Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  12.00 1.15% 1,054.00 1,054.00 1,056.00 1,060.00 1,020.00 1,042.00 157,724 16:29:59
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 87.7 -6.6 0.0 - 867

Oxford Biomedica PLC Holdings in Company

05/02/2021 1:22pm

UK Regulatory (RNS & others)

Oxford Biomedica (LSE:OXB)
Historical Stock Chart

From Jan 2021 to Apr 2021

Click Here for more Oxford Biomedica Charts.


RNS Number : 1974O

Oxford Biomedica PLC

05 February 2021

TR-1 annoucement of major holdings

Oxford, UK - 5 February 2021: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Vulpes Testudo/Lifesciences Fund, has advised the Group that on 4 February 2021 it sold 970,000 ordinary shares of 50p each in the Group. The shares have been acquired by a subsidiary of Vitruvian Investment Partnership III, a fund managed by Vitruvian Partners LLP. Vitruvian Partners is a leading global growth investment firm with EUR10bn AUM, and has supported some of Europe's most successful high growth innovators. They are highly respected with a long term focus and strong interest in cell and gene therapy.

Martin Diggle from VulpesTestudo/Lifesceinces Fund said: "Through the recent sale of a portion of our holding to Vitruvian Partners LLP, Oxford Biomedica gains another well respected long-term shareholder. We are excited about the future for the Group, remain fully supportive of the business and continue to retain a significant shareholding."

 NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and 
  to the FCA in Microsoft Word format if possible) (i) 
 1a. Identity of the issuer or the                                       OXFORD BIOMEDICA PLC 
  underlying issuer of existing shares 
  to which voting rights are attached 
  (ii) : 
 1b. Please indicate if the issuer is a non-UK issuer (please mark with 
  an "X" if appropriate) 
 Non-UK issuer 
 2. Reason for the notification (please mark the appropriate box or boxes 
  with an "X") 
 An acquisition or disposal of voting rights                                                           X 
 An acquisition or disposal of financial instruments 
 An event changing the breakdown of voting rights 
 Other (please specify)(iii) : 
 3. Details of person subject to the notification obligation (iv) 
 Name                                                         VULPES LIFE SCIENCES FUND 
                                                               VULPES TESTUDO FUND 
 City and country of registered office                        CAYMAN ISLANDS 
  (if applicable) 
 4. Full name of shareholder(s) (if different from 3.) (v) 
 City and country of registered office 
  (if applicable) 
 5. Date on which the threshold was                           04/02/2021 
  crossed or reached (vi) : 
 6. Date on which issuer notified (DD/MM/YYYY):               05/02/2021 
 7. Total positions of person(s) subject to the notification obligation 
                              % of voting       % of voting rights    Total of both   Total number 
                            rights attached      through financial     in % (8.A +     of voting rights 
                            to shares (total        instruments            8.B)        of issuer (vii) 
                                of 8. A)           (total of 8.B 
                                                    1 + 8.B 2) 
                          ------------------  ---------------------  --------------  -------------------- 
 Resulting situation 
  on the date 
  on which threshold 
  was crossed 
  or reached               11.86%              0%                     11.86%          9,768,615 
                          ------------------  ---------------------  --------------  -------------------- 
 Position of 
  previous notification 
  applicable)              -                   0% 
                          ------------------  ---------------------  --------------  -------------------- 
 8. Notified details of the resulting situation on the date on which the 
  threshold was crossed or reached (viii) 
 A: Voting rights attached to shares 
 Class/type          Number of voting rights (ix)                        % of voting rights 
  ISIN code 
  (if possible) 
                            Direct                   Indirect                     Direct                  Indirect 
                      (Art 9 of Directive       (Art 10 of Directive        (Art 9 of Directive     (Art 10 of Directive 
                          2004/109/EC)              2004/109/EC)           2004/109/EC) (DTR5.1)        2004/109/EC) 
                            (DTR5.1)                 (DTR5.2.1)                                          (DTR5.2.1) 
 GB0006648157        9,768,615                                           11.86% 
                    ----------------------  --------------------------  -------------------------  --------------------- 
  8. A                                   9,768,615                                           11.86% 
                    --------------------------------------------------  ------------------------------------------------ 
 B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC 
  (DTR5.3.1.1 (a)) 
 Type of financial   Expiration   Exercise/                       Number of voting                  % of voting rights 
  instrument          date         Conversion Period               rights that may 
                      (x)          (xi)                            be acquired if 
                                                                   the instrument 
                    -----------  ------------------------------  --------------------------------  --------------------- 
                                  SUBTOTAL 8. B 1 
                                 ------------------------------  --------------------------------  --------------------- 
 B 2: Financial Instruments with similar economic effect according to 
  Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) 
 Type of        Expiration        Exercise/             Physical or           Number of             % of voting rights 
  financial      date (x)          Conversion            cash                  voting rights 
  instrument                       Period (xi)           settlement 
               ----------------  --------------------  --------------------  -------------------- 
                                                        SUBTOTAL 8.B.2 
                                                       --------------------  -------------------- 
 9. Information in relation to the person subject to the notification 
  obligation (please mark the 
  applicable box with an "X") 
 Person subject to the notification obligation is not controlled                        X 
  by any natural person or legal entity and does not control any other 
  undertaking(s) holding directly or indirectly an interest in the 
  (underlying) issuer(xiii) 
 Full chain of controlled undertakings through which the voting rights 
  and/or the 
  financial instruments are effectively held starting with the ultimate 
  controlling natural person or legal entity(xiv) (please add additional 
  rows as necessary) 
    Name (xv)        % of voting rights      % of voting rights       Total of both if 
                       if it equals or        through financial        it equals or is 
                      is higher than the      instruments if it        higher than the 
                     notifiable threshold    equals or is higher     notifiable threshold 
                                             than the notifiable 
                   ----------------------  ---------------------  ------------------------ 
 10. In case of proxy voting, please identify: 
 Name of the proxy holder 
 The number and % of voting rights 
 The date until which the voting rights 
  will be held 
 11. Additional information (xvi) 
 Place of completion   London, UK 
 Date of completion    04 February 2021 
 Contact name:        Natalie Walter 
 Contact telephone 
  number:             01865 783000 


   Oxford Biomedica plc 
   John Dawson, Chief Executive Officer        T: +44 (0)1865 783 000 
   Stuart Paynter, Chief Financial Officer     T: +44 (0)1865 783 000 
   Catherine Isted, Head of Corporate          T: +44 (0)1865 954 161 / E: 
   Development & IR 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew Neal              T: +44 (0)20 3709 5700 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

February 05, 2021 08:22 ET (13:22 GMT)

1 Year Oxford Biomedica Chart

1 Year Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

1 Month Oxford Biomedica Chart
ADVFN Advertorial
Your Recent History
Oxford Bio..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210416 22:06:03